Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for refractory lupus nephritis (Renji Hospital single-arm observational Phase II)
ChiCTR2400081359Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in refractory lupus nephritis (RLN) and systemic lupus erythematosus (SLE), sponsored by Renji Hospital. Primary endpoints: eGFR, 24-hour proteinuria and 1 more. Started Feb 2024; status: completed.
02
Drugs
abatacept
03
Conditions
refractory lupus nephritis (RLN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2400081359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081359.